Google Cloud unveiled a new product suite to make medical imaging data more interoperable and useful via artificial intelligence. Hackensack Meridian Health has begun using it to detect metastasis in prostate cancer patients earlier, and Hologic is using it to strengthen its diagnostic platform that screens women for cervical cancer.
Mobidiag offers multiplex testing, which is the ability to test for multiple pathogens from a single test sample. Hologic said the acquisition will enable the company to enter the acute care test market, which is projected to grow in a post-pandemic world.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The EUAs follow the ones the agency gave last week to Roche and Thermo Fisher Scientific. The agency is also allowing states to take greater responsibility for authorizing tests for the SARS-CoV-2 virus.
Medical device companies, hospitals, doctors and some patient advocates have put their marketing muscle and millions of dollars behind 3D mammograms, even though the U.S. Preventive Services Task Force hasn't found it to be more effective than traditional mammograms.
Also, Hologic said that a study of women screened for breast cancer over multiple years using its Genius 3D mammography system showed a significant drop in recalls.
Medical device company Hologic will continue with a patent infringement case. The original lawsuit alleged that SenoRx violated Hologic's patents for its MammoSite brachytherapy balloon catheter device. The system delivers radiation to the cavity left from the removal of cancerous breast tissue during lumpectomy.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Early stage biotech companies looking for venture capital have always found it hard to get VC funding, but it looks like it's only going to get harder. A panel of VCs at the CED Biotech/Life Science conference in Raleigh, North Carolina said that VCs want for surer investments likely to make a strong market impact.
A new innovative medical device from Hologic for performing mammograms was approved by the U.S. Food and Drug Administration. The Selenia FDA approval means physicians will have access to "unique and innovative 3-D technology that could significantly enhance existing diagnosis and treatment approaches," Center for Devices & Radiological Health chief Dr. Jeffrey Shuren stated.
A new private-label deal will see Hologic Inc. distributing a soft tissue biopsy instrument manufactured by Angiotech Pharmaceuticals Inc. Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) inked a three-year, private-label deal with Bedford, Mass.-based Hologic Inc. (NSDQ:HOLX). Under the terms of the agreement, Vancouver-based Angiotech will supply Hologic with its soft tissue biopsy device for breast biopsies. The […]
Hologic Inc.’s (NASDAQ:HOLX) long wait to launch its 3D breast exam system is close to over. The company received an “approvable letter” from the Food & Drug Administration for its Selenia Dimensions 3-D digital mammography tomosynthesis system. The letter indicates that the final approval of the device maker’s pre-market approval application for the breast exam […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Hologic Inc.'s (NASDAQ:HOLX) Selenia Dimensions 3D digital mammography tomosynthesis system edged closer to approval from the Food & Drug Administration last week.
Hologic Inc. (NSDQ:HOLX) agreed to acquire Sentinelle Medical Inc. for $85 million plus contingencies. The deal calls for Bedford, Mass.-based Hologic to pay a “two-year contingent earn out,” according to a press release, for Toronto-based Sentinelle, which makes MRI breast coils, tables and visualization software. The earn-out involves cash payments equal to a multiple of […]
C.R. Bard Inc. acquires SenoRx Inc. for $200 million, or $11 per share. C.R. Bard Inc. (NYSE:BCR) closed its acquisition of SenoRx Inc. (NSDQ:SENO). The Murray Hill, N.J.-based device conglomerate bought Irvine, Calif.-based SenoRx for about $200 million, or $11 per share. C.R. Bard made the purchase at a 14 percent premium over SenoRx’s May […]
Ethicon Endo-Surgery Inc. and a subsidiary of Hologic Inc. have settled their patent infringement disagreements with a $12.5 million payment to Ethicon and the promise to share royalties from selling each other's breast cancer biopsy devices.